NEW YORK, Nov. 6, 2023 (GLOBE NEWSWIRE) — Ginko Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) are building a leading platform for cell programming and biosecurity. Today, we announced that we are expanding our services.Collaborate with the Centers for Disease Control and Prevention (CDC) Traveler-based Genomic Surveillance Program (TGS) In addition to SARS-CoV-2, it will test for more than 30 additional priority pathogens. TGS is a flexible, multimodal platform consisting of three complementary approaches to collecting samples from international travelers arriving at U.S. airports. This includes voluntary nasal swabs, aircraft wastewater, and airport wastewater sampling to enhance early detection of new SARS-CoV-2 variants and more. Eliminate pathogens and close global surveillance gaps.
Concentric by Ginkgo, the biosecurity and public health division of Ginkgo Bioworks, and XpresCheck by XWELL have partnered to expand their collaboration with the CDC to identify more than 30 emerging viruses, including several seasonal respiratory pathogens, including: Monitoring bacteria, targets for antimicrobial resistance. Influenza A and B, RSV, SARS-CoV-2. Partners continue to help CDC improve TGS’ ability to detect pathogens as early as possible, enabling the best public health response.
The program expansion will begin at four of the seven major international airports covered by the program: New York, JFK, San Francisco, Boston, Washington DC, and Dulles.
Since its inception in 2021, the TGS program has quickly adapted to the evolving pandemic in real time, proving to be a nimble and valuable asset to U.S. public health officials. As of October 2023, TGS has engaged more than 370,000 travelers with her ongoing enrollment of approximately 6,000 volunteer travelers each week. The program is open to travelers from more than 135 countries from all World Health Organization regions. Since its inception, the program has sequenced more than 14,000 samples and made genomic data available to several public health platforms to enable further analysis. This enhancement allows you to monitor program functionality and change focus as needed to identify priority pathogens. TGS can strengthen global surveillance systems, especially in the face of limited testing and sequence information.
“By building a sustainable and scalable infrastructure capable of detecting biological threats beyond SARS-CoV-2, the TGS program will become a global leader in the evolution of biosecurity,” said Ginkgo Bioworks Biosecurity Director General Manager Matt McKnight said. “Continuous surveillance can help us understand how the pathogen spreads around the world and give authorities early warning.”
TGS was the first to detect many new SARS-CoV-2 variants entering the U.S., including Omicron BA2, BA3, XBB, and BA2.86, six weeks before they were reported in other countries. demonstrated the program’s valuable capabilities. Early variants.
“As air travel exceeds pre-pandemic levels and the spread of COVID-19 and other viruses continues, continued testing is critical,” said XpresCheck CEO Ezra Ernst. Stated. “The data we collect provides critical insights to help public health officials know how best to protect our country from evolving viral threats. Volunteers swab noses for national security and public health I would like to thank everyone.”
About EXWELL Co., Ltd.
XWELL, Inc. (Nasdaq: XWEL) is a leading global health and wellness holding company operating multiple brands: XpresSpa®Treat™, Naples Wax Center®,XpresCheck® and HyperPointe™.
- XpresSpa is a leading airport retailer of wellness services and related products, with 30 stores in 14 airports worldwide.
- Treat is a travel wellness brand, a fully integrated concept that blends technology and traditional brick-and-mortar products to offer travelers a holistic approach to physical and mental health.
- Naples Wax Center is a group of upscale skin care boutiques in Florida and is the first step in building the company’s retail portfolio outside of airports.
- XpresCheck is a screening and diagnostic testing provider in partnership with the CDC and Concentric by Ginkgo that conducts biosurveillance monitoring within airports to detect new SARS-CoV2 variants of interest and concern, as well as national and Identify other pathogens that invade the. world.
- HyperPointe is a leading digital healthcare and data analytics company serving the global healthcare industry.
About Ginko Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, offering flexible end-to-end services to solve organizational challenges across diverse markets, from food and agriculture to pharmaceuticals and industrial and specialty chemicals. I am. Concentric by Ginkgo, Ginkgo’s biosecurity and public health division, is the global leader in biosecurity, empowering governments, communities, and public health leaders to prevent, detect, and respond to a wide range of biological threats. We are building a new infrastructure. For more information, please visit: ginkgobioworks.com and concentricbyginkgo.complease read our blogor follow us on our social media channels like X (formerly Twitter) (@ginkgo and @ConcentricByGinkgo), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), thread (@GinkgoBioworks), or linkedin.
Forward-looking statements about XWELL, Inc.
This press release may contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by, or otherwise containing the word “.” “believes,” “expects,” “anticipates,” “estimates,” “plans,” “intends,” “should,” “seeks.” ”, “future”, “continuing” or the negation of such terms, or any other equivalent term. Forward-looking statements regarding expectations regarding future results or events, including our current plans and expectations regarding Naples Wax Center’s business and operations and future store openings, are based on information available to XWELL as of the date hereof. ,There is no guarantee. relates to our future performance, and actual results may differ materially from the results and expectations discussed. Additional information regarding these and other risks can be found in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. included in the document. All subsequent written and oral forward-looking statements regarding XWELL or other matters are attributable to XWELL or its agents and are expressly qualified in their entirety by the cautionary statements above. XWELL undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that may occur after the date of this document.
Ginkgo Bioworks Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo’s biosecurity platform. These forward-looking statements generally include “believe,” “could,” “anticipate,” “could,” “expect,” “anticipate,” “estimate,” “intend,” ” “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “would”, “would”, “would”, “will continue” ”, “likely to result”, and similar expressions. Forward-looking statements are predictions, forecasts or other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual future events may cause the forward-looking statements in this press release to differ materially, including, but not limited to: (i) fluctuations in the price of Ginko’s securities due to various factors, including changes in the competitive environment; (ii) our ability to execute our business plans, forecasts and other expectations and to identify and realize additional challenges; business opportunities; (iii) the risk of reduced demand for products using synthetic biology; (iv) uncertainty regarding the demand for passive monitoring programs and biosecurity services; (v) changes in the biosecurity industry, including due to technological advances; new competition and industry demands, evolving standards and regulations; (vi) the Company’s ability to realize the expected benefits of merger and acquisition transactions; (vii) legal proceedings against Ginkgo, including the outcome of recent acquisitions; results, (viii)) our ability to realize the anticipated benefits and success of our Foundry Platform program; (ix) our successful development of engineered cells, bioprocesses, data packages or other deliverables; (x) our customers’ product development or commercialization success; The foregoing list of factors is not exhaustive. The foregoing factors and other risks and Uncertainty must be carefully considered. Other documents may be filed with the SEC by Ginkgo from time to time. These filings identify and address other important risks and uncertainties that could cause actual events or results to differ materially from those contained in the forward-looking statements. . Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Ginkgo undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. There is no intention to do so. There is no guarantee that Ginkgo will achieve expectations.
